Skip to main content
Premium Trial:

Request an Annual Quote

Software Firm Partners with IBM to Develop, Distribute New Products


WILMINGTON, NC--Belmont Research, a software development firm here whose products have genomics applications, has entered into a strategic partnership with IBM to develop and distribute software to aid pharmaceutical companies' research and development efforts. Under terms of the agreement, IBM will become the exclusive US and European distributor of Belmont's CrossGraphs and TableTrans software, which are used by pharmaceutical and biotechnology companies to review, consolidate and report complex scientific and operational data.

Belmont is a subsidiary of Pharmaceutical Product Development. CrossGraphs is a data visualization and multigraphic reporting system that aids drug discovery through high-throughput compound screening and gene expression monitoring, and facilitates clinical development through data management, medical review of drug safety, and computer-assisted new drug applications. TableTrans--a visual programming tool--supports rapid specification, review, and documentation of database transformations for data restructuring and analysis. It is used to ex change data with contractors and partners, convert data to match specific coding conventions, and pull and organize databases for analysis.

Under terms of the alliance the partners will also develop products and services related to ClinWare, IBM's electronic data capture system, with Belmont providing additional product components to extend ClinWare's capabilities. The two firms will also provide remote data entry, electronic data interchange, and database migration consulting and services through IBM, with the intention of helping customers implement and manage a transition to a more effective electronic environment for data capture and validation.

"IBM's global presence and strong commitment to offering comprehensive information solutions for pharmaceutical R&D complement Belmont's software technology and experience in meeting industry data-management needs," explained Fred Eshelman, Pharmaceutical Product Develop ment's CEO. "We anticipate that the new relationship will give Belmont significantly increased distribution for its present software products and will lead to the development of attractive new product and service offerings."

Filed under

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.